Keyphrases
Outcome-based Contracts
72%
Pricing Method
72%
Meta-analysis
54%
Osimertinib
42%
Monte Carlo Simulation
36%
Combination Therapy
36%
Talimogene Laherparepvec (T-VEC)
36%
Ipilimumab
36%
Economic Evaluation
36%
Acquisition Cost
31%
Outcome-based Pricing
29%
Non-small Cell Lung Cancer (NSCLC)
29%
Quality-adjusted Life Years
25%
Willingness to Pay
22%
Confidence Interval
22%
Incremental Cost-effectiveness Ratio
21%
Progression-free Survival
21%
Reference Dependence
21%
Monotherapy
21%
Melanoma
20%
Acute Care
18%
Immune-mediated Colitis
18%
Risk Ratio
18%
New York Intellectuals
18%
Breast Cancer Patients
18%
Heart Failure
18%
Targeted Treatment
18%
Sudden Sensorineural Hearing Loss (SSNHL)
18%
Arrears
18%
Civility
18%
Hospitalized Adults
18%
Atypical Bacteria
18%
Subjective Cognitive Decline
18%
Pharmacist Intervention
18%
Palestinians
18%
Scholars of Color
18%
Foreign Countries
18%
Bucindolol
18%
Carvedilol
18%
β1-adrenergic Receptor
18%
Adrenergic Receptor Polymorphisms
18%
SEER-Medicare
18%
Technical Guidelines
18%
Macrolide Antibiotics
18%
Black Lives
18%
Liberation Struggle
18%
Skin Imaging
18%
Integrative Analysis
18%
Scoping Review
18%
Prospective Cohort Study
18%
Pharmacology, Toxicology and Pharmaceutical Science
Osimertinib
100%
Non Small Cell Lung Cancer
66%
Melanoma
54%
Ipilimumab
44%
Epidermal Growth Factor Receptor
42%
Combination Therapy
37%
Talimogene Laherparepvec
36%
Chemotherapy
36%
Pancreas Cancer
36%
Gemcitabine
36%
Progression Free Survival
25%
Clinical Trial
25%
Monotherapy
23%
Macrolide
22%
Adverse Event
19%
Epileptic Absence
19%
Pharmacoeconomics
18%
Carcinoembryonic Antigen
18%
Fondaparinux
18%
Hydrocortisone
18%
Perception Deafness
18%
Carvedilol
18%
Septic Shock
18%
Bucindolol
18%
Heart Failure
18%
Beta 1 Adrenergic Receptor
18%
Immune Checkpoint Inhibitor
18%
Community Acquired Pneumonia
18%
Comorbidity
18%
Antibiotic Agent
18%
Metastatic Melanoma
18%
Hypothyroidism
18%
Chronic Obstructive Lung Disease
18%
Capecitabine
14%
Antibiotics
13%
Nivolumab
10%
Randomized Controlled Trial
9%
Lactam
9%
Diarrhea
9%
Pembrolizumab
7%
Paclitaxel
7%
Random Effects Model
6%
Activated Protein C
6%
Overall Survival
5%
Oxaliplatin
5%
Cisplatin
5%
Medicine and Dentistry
Nodular Melanoma
36%
Skin Defect
36%
Immune Checkpoint Inhibitor
36%
Medicare
20%
Image Quality
18%
Abdominal Fat
18%
Septic Shock
18%
Hydrocortisone
18%
Dermatology
18%
Beta 1 Adrenergic Receptor
18%
Systematic Review
18%
Elderly Patient
18%
Cost Benefit Analysis
18%
Teledermatology
18%
Low and Middle Income Countries
18%
Meta-Analysis
18%
Ebolavirus
18%
Community-Acquired Pneumonia
18%
Colitis
18%
Hypothyroidism
18%
Virus Infection
15%
CTLA-4
13%
Programmed Cell Death
13%
Adverse Event
13%
Antibiotics
13%
Health Care Cost
12%
Nivolumab
11%
Ipilimumab
9%
Drug Therapy
9%
Pembrolizumab
9%
Body Mass Index
9%
Clinical Study
9%
Lactam
9%
Diarrhea
9%
Electronic Health Record
9%
Randomized Controlled Trial
9%
Cost-Effectiveness Analysis
7%
Corticosteroid Therapy
7%
Iliac Crest
6%
Activated Protein C
6%
Visceral Fat
6%
Linear Regression Analysis
6%
Disability Adjusted Life Years
5%
Infection
5%